Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 9Triple Negative Breast Neoplasms 5Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Inflammatory Breast Neoplasms 2Carcinoma, Transitional Cell 2Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Liposarcoma 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HR+HER2- Breast Cancer 1Colorectal Neoplasms 1

Interventions

Specimen Handling 5Nivolumab 4avelumab 3Magnetic Resonance Spectroscopy 3pembrolizumab 2cabozantinib 2atezolizumab 2Ipilimumab 2Immunoglobulin G 2Disulfides 2CTLA-4 Antigen 2Biopsy 2tremelimumab 1tocilizumab 1relatlimab 1guadecitabine 1eribulin 1erdafitinib 1enfortumab vedotin 1durvalumab 1Watchful Waiting 1Propranolol 1Observation 1Gemcitabine 1Doxorubicin 1Cystoscopy 1Contrast Media 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Ureteral Neoplasms × eribulin × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡